Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for ...

The approved ANDA is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal XR extended-release tablets in strength of ...

The stock hits an intraday high on Thursday, October 3, 2024, after getting approval from USFDA for general medication drug.

Lamotrigine extended-release tablets have an estimated market size of $163 million, as per data for twelve months ending June ...

Mahindra Group, Max Life Insurance, and Alembic Pharmaceuticals are leading internships under a new central scheme, with ...

The estimated market value for Lamotrigine Extended-Release Tablets is approximately $163 million for the year ending June ...

This approval adds to Alembic Pharma's growing portfolio, which now includes 216 ANDA approvals from the USFDA, comprising ...

Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug ...

Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Extended-Release Tablets USP, 200 mg, 250 ...

The FDA has approved Alembic's generic Albenza and generic Invega. Alembic has received The Food and Drug Administration’s ...

Alembic Pharmaceuticals receives FDA approval for Paliperidone Tablets, trading at ₹1,179.95 on NSE, expanding its global ...